Przedstawiamy wybór publikacji naukowych związanych z immunoterapią IOZK. Możesz użyć filtrów, aby dokonać wyboru według typów nowotworów i metod lub wprowadzić wyszukiwane hasła.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-09-21 / Int J Hyperthermia 2011;27(2):180-6https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-09-21 / Int J Hyperthermia 2011;27(2):180-62010-09-21 00:00:002019-02-15 09:17:26Intracavity hyperthermia in nasopharyngeal cancer: a phase III clinical study
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-09-07 / Cancer Res. 2010 Sep;70(18):7093-101https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-09-07 / Cancer Res. 2010 Sep;70(18):7093-1012010-09-07 00:00:002019-02-15 08:40:15IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-09-01 / Dan Med Bull 2010 Sep;57(9):B4171https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-09-01 / Dan Med Bull 2010 Sep;57(9):B41712010-09-01 00:00:002019-02-15 08:46:06Dendritic cell vaccination of patients with metastatic colorectal cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-09-01 / PLoS ONE 2010 Sep;5(9)https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-09-01 / PLoS ONE 2010 Sep;5(9)2010-09-01 00:00:002019-02-15 08:52:57Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-78https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-08-24 / Clin. Cancer Res. 2010 Oct;16(20):5067-782010-08-24 00:00:002019-02-15 08:49:24Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-704https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-08-01 / Zhonghua Nan Ke Xue 2010 Aug;16(8):698-7042010-08-01 00:00:002019-02-15 08:52:54[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-08-01 / Nat. Rev. Immunol. 2010 Aug;10(8):580-93https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-08-01 / Nat. Rev. Immunol. 2010 Aug;10(8):580-932010-08-01 00:00:002019-02-15 08:52:58Prostate cancer as a model for tumour immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-6https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-08-01 / Sheng Wu Gong Cheng Xue Bao 2010 Aug;26(8):1031-62010-08-01 00:00:002019-02-15 09:21:42[Progress in using Newcastle disease virus for tumor therapy: a review]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-6https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-08-01 / Zhongguo Fei Ai Za Zhi 2010 Aug;13(8):773-62010-08-01 00:00:002019-02-15 09:21:46[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-08-01 / Surgery 2010 Aug;148(2):325-34https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-08-01 / Surgery 2010 Aug;148(2):325-342010-08-01 00:00:002010-08-01 00:00:00Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-19https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-07-27 / Pigment Cell Melanoma Res 2010 Oct;23(5):607-192010-07-27 00:00:002010-07-27 00:00:00Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg002010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-64https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg2010-07-07 / Br. J. Haematol. 2010 Sep;150(5):554-642010-07-07 00:00:002019-02-15 08:50:54Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients
Intracavity hyperthermia in nasopharyngeal cancer: a phase III clinical study
Genetically engineered oncolytic Newcastle disease virus effectively induces sustained remission of malignant pleural mesothelioma
IFN{gamma} markedly cooperates with intratumoral dendritic cell vaccine in dog tumor models
Dendritic cell vaccination of patients with metastatic colorectal cancer
Harnessing naturally occurring tumor immunity: a clinical vaccine trial in prostate cancer
Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma
Dendritic cell vaccination in combination with anti-CD25 monoclonal antibody treatment: a phase I/II study in metastatic melanoma patients
Dendritic cells-mediated CTLs targeting hepatocellular carcinoma stem cells
The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: a powerful molecular adjuvant for DNA anti-tumor vaccination
Ascorbate exerts anti-proliferative effects through cell cycle inhibition and sensitizes tumor cells towards cytostatic drugs
Global sensitivity analysis and model-based reactive scheduling of targeted cancer immunotherapy
[Auto-dendritic cell vaccines pulsed with PSA, PSMA and PAP peptides for hormone-refractory prostate cancer]
Prostate cancer as a model for tumour immunotherapy
[Progress in using Newcastle disease virus for tumor therapy: a review]
[Anti-tumor immunity of Newcastle disease virus HN protein is influenced by differential subcellular targeting]
Hyperthermia potentiates oncolytic herpes viral killing of pancreatic cancer through a heat shock protein pathway
Dendritic cell vaccination in human melanoma: relationships between clinical effects and vaccine parameters
Human myeloid dendritic cells for cancer therapy: does maturation matter?
Induction of complete and molecular remissions in acute myeloid leukemia by Wilms‘ tumor 1 antigen-targeted dendritic cell vaccination
Optimizing dendritic cell-based immunotherapy in multiple myeloma: intranodal injections of idiotype-pulsed CD40 ligand-matured vaccines led to induction of type-1 and cytotoxic T-cell immune responses in patients